Andecaliximab added to mFOLFOX6 chemotherapy did not improve survival in patients with advanced gastric/GEJ cancer, except for one subset — those 65 years and older.
Medscape Medical News
Original Article: MMP9 Inhibitor Added to Chemo in Gastric/GEJ Cancer